Biosimilar Monoclonal Antibodies (mAbs) Market Trends 2022 | Segmentation, Outlook, Industry Report to 2028

The Biosimilar Monoclonal Antibodies (mAbs) Market size is expected to grow at an annual average of 29% during 2021-2027. Biosimilar monoclonal antibodies (mAbs) are large, complex proteins in the family of biosimilars used by the immune system to identify and neutralize foreign substances such as bacteria and viruses. These antibodies are usually given to treat diseases such as rheumatoid arthritis, Hodgkin’s lymphoma, and chronic lymphocytic leukemia.

The following segmentation are covered in this report:

By Application

• Chronic & Autoimmune Diseases
• Oncology
• Others

By Type

• Synthetic Chemicals
• Biopharmaceuticals
• Others

Company Profile

• Amgen Inc.
• BIOCAD
• Biocon Ltd.
• BioXpress Therapeutics SA
• Boehringer Ingelheim International GmbH
• Celltrion Inc.
• Coherus BioSciences Inc.
• Intas Pharmaceuticals Ltd.
• Novartis AG
• Pfizer Inc.

Scope of the report

The research study analyses the Biosimilar Monoclonal Antibodies (mAbs) Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by Biosimilar Monoclonal Antibodies (mAbs) Market Report

• What was the Biosimilar Monoclonal Antibodies (mAbs) Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2021-2027)
• What will be the CAGR of Market during the forecast period (2021-2027)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2021-2027).
• Which manufacturer/vendor/players in the Biosimilar Monoclonal Antibodies (mAbs) Market was the market leader in 2020?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.